ARRIVENT BIOPHARMA IN

34.19

08-November-24 15:59:57

15 minutes delayed

Stocks

-1.44

-4.04%

Today's range

33.17 - 36.37

ISIN

N/A

Source

NASDAQ

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

09 Sep 2024 12:05:00 By Nasdaq GlobeNewswire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results

14 Aug 2024 16:01:00 By Nasdaq GlobeNewswire
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

12 Aug 2024 08:00:00 By Nasdaq GlobeNewswire
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

05 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
ArriVent Appoints John Hohneker, M.D., to its Board of Directors

16 May 2024 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.